Invivyd

This month, we are pleased to highlight Timothy Lee, our Chief Commercial Officer. Hear about Tim's commitment to protecting the most vulnerable people from serious viral threats of today and tomorrow. 

Vaccines contribute to a form of active immunity by triggering the immune system to produce antibodies that can fight pathogens. Unfortunately, people who have impaired immune systems, such as the #immunocompromised, may not have an adequate immune response to vaccines. To protect this vulnerable population from circulating viral threats such as #COVID19, we are on a mission to deliver antibody-based therapies, which can support a form of passive immunity. Learn more about our work here: https://lnkd.in/euWWXjgm (Immunity can take many forms. The examples provided are for illustrative purposes only and not intended to be comprehensive.)

Earlier today, we were pleased to announce positive 12-month exploratory clinical efficacy data from the company’s ongoing CANOPY Phase 3 clinical trial of pemivibart. We invite you to read our press release for more information. https://lnkd.in/e_C2kNYg #covid19

Meet Dayna Mcadams, BSN, Senior Director, Head of Regional Clinic Specialists. She shares the personal reason why she chose to join the Invivyd team.

We are pleased to highlight Margarita Malhotra, CIPP, CCEP, our Director, Corporate Compliance. She was recently recognized by a colleague for her fabulous support and advocacy while always keeping compliance and Invivyd values at the forefront. A big thank you to Margarita for showcasing the Vydian spirit! #weareinvivyd

Attending #IDWeek2024? Join us today, Thursday, October 17th at 1:15pm in Learning Lounge 3 for a session with our Chief Scientific Officer, Robert Allen, to learn more about our Invymab platform. 

Attending #IDWeek2024? Stop by our booths (# 635 and # 643) or join us for one of our presentations where we will presenting #COVID19 data on our investigational antibody-based therapy for immunocompromised individuals. Anna Holmes will be presenting an oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY study on Thursday, October 17th at 10:30am. On Saturday, October 19th at 12:15 PM Amanda Copans, PharmD will present a poster on results from a phase 1 First in Human study and Pamela Hawn will present a poster on pharmacokinetics and serum virus neutralizing antibody titers in the CANOPY trial. These results are the latest demonstration of our commitment to protecting the most vulnerable people from serious viral threats of today and tomorrow.  Read more about our progress: https://lnkd.in/g-t5t7wE

This month, we are pleased to highlight Julie Green, our Chief Human Resources Officer and Head of Communications. Hear from Julie about what makes Invivyd unique.

It is essential to prioritize mental health in the workplace. At Invivyd, we are proud to partner with KGA, Inc., a leading employee assistance program to offer our employees a broad range of services from mental health counseling to organizational well-being. #WorldMentalHealthDay

Yesterday’s innovations fuel tomorrow’s breakthroughs. That’s why INVIVYD never rests. We're seeking next gen prevention for diseases like #COVID19, and we won't stop until we've found them. Stay tuned to see our discoveries. #SeekingMoreProtection